Most Read Articles
Pearl Toh, 3 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Elvira Manzano, 3 days ago
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
Tristan Manalac, 5 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.

Certain biologics for psoriasis may reduce cardiometabolic burden

30 Apr 2021

In the treatment of patients with psoriasis, use of certain biologic drugs appears to reduce aortic vascular inflammation and cardiometabolic risk biomarkers, including C-reactive protein (CRP) and interleukin (IL)-6, according to a study.

Researchers performed a meta-analysis of studies investigating the effect of licensed biologic therapies on imaging and biomarkers of cardiovascular disease (CVD) risk in patients with psoriasis. Of the five studies included in the final examination, two were retained for the meta-analysis.

Compared with placebo, adalimumab conferred no significant benefit for aortic vascular inflammation at weeks 12–16. Likewise, both adalimumab and secukinumab showed no beneficial effect on imaging biomarkers (aortic vascular inflammation or flow mediated dilatation) relative to placebo. The only exception was ustekinumab, which produced a reduction in aortic vascular inflammation at week 12 but not at week 52 after the open-label extension period.

Meanwhile, the strongest reduction in blood-based cardiometabolic risk biomarkers was seen with adalimumab (CRP, tumour necrosis factor-alpha, IL-6, and glycoprotein acetylation) and phototherapy (CRP and IL-6) when compared with placebo.

The surrogate marker findings demonstrate that ustekinumab lowers aortic vascular inflammation, while tumour necrosis factor inhibitor and phototherapy induce CRP and IL-6 decline. Additional randomized controlled trials evaluating cardiovascular events are warranted to inform clinical practice.

Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Elvira Manzano, 3 days ago
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
Tristan Manalac, 5 days ago
Visceral fat area is the strongest indicator of mobility disability among obese, community-dwelling, older adults, according to a recent Singapore study.